Summary
Signal counts
Assets tracked: 3
Watchlist assets: 3
Registry stop assets: 0
Sponsor overview
AbbVie
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03386513 | https://clinicaltrials.gov/study/NCT05041257 | https://clinicaltrials.gov/study/NCT02606305 | https://clinicaltrials.gov/study/NCT02674568
Assets
Linked programs
- IMGN632: Timeline Staleness Signal (2/5)
- Mirvetuximab soravtansine: Watchlist Signal (2/5)
- Rovalpituzumab tesirine: Operational Burden Signal (2/5)